CHMP Backs Nezglyal for Cerebral ALD in Boys
CHMP Nezglyal leriglitazone cerebral ALD recommendation under exceptional circumstances advances the first potential pharmacological option for a narrowly defined paediatric population. EMA published the July plenary outcome on 24 July 2026; Minoryx and Neuraxpharm expect a Commission decision by end-September.
Contents9 sections
Key Takeaways
- CHMP recommended Nezglyal under exceptional circumstances for cerebral adrenoleukodystrophy.
- Target population cited: boys 2–12 with Gd-negative MRI lesions and NFS 0 or 1.
- Evidence package: NEXUS Phase 2/3 plus compassionate-use experience.
- No approved pharmacological cALD treatments exist in the EU today, per the sponsors.
Nezglyal CHMP opinion at a glance
| Field | Detail |
|---|---|
| Product | Nezglyal (leriglitazone) |
| Sponsors | Minoryx Therapeutics; Neuraxpharm (EU commercial) |
| Mechanism | Oral, brain-penetrant selective PPAR-gamma agonist |
| Regulator action | CHMP positive opinion, exceptional circumstances (23 July 2026) |
| Population cited | Males with ALD, ages 2–12; Gd-negative lesions; NFS 0–1 |
| Key study | Phase 2/3 NEXUS (+ real-world / compassionate use) |
| Next step | European Commission decision (companies: end-September 2026) |
What did EMA and the sponsors announce?
EMA's July CHMP highlights listed Nezglyal among twelve medicines recommended for approval, specifically noting an exceptional-circumstances path for cerebral adrenoleukodystrophy. Separately, Minoryx and Neuraxpharm detailed the paediatric Gd-negative, low-NFS indication and said Neuraxpharm will commercialise in Europe after authorisation.
Primary sources: EMA's July 2026 CHMP meeting highlights and Minoryx and Neuraxpharm's 24 July GlobeNewswire release.
Why is cALD so hard to treat?
Cerebral ALD features rapidly progressive demyelinating brain lesions that can lead to severe disability or death within a few years once the cerebral phenotype declares. Haematopoietic stem-cell transplantation remains a disease-modifying option for selected early patients, but pharmacological alternatives have been lacking in the EU. Exceptional-circumstances authorisation allows CHMP to recommend approval when comprehensive data cannot be generated under normal conditions, typically with post-authorisation obligations.
Orphan-designation context for rare diseases is summarized on EMA's orphan designation overview.
What should clinicians watch?
- Final SmPC wording on MRI Gd status and NFS thresholds
- How Nezglyal sequences with or bridges to HSCT
- Exceptional-circumstances follow-up studies EMA will require
- Adult Gd-positive programmes such as CALYX, which remain outside this opinion
The recommended label is narrower than broader adult or Gd-enhancing populations discussed in earlier development narratives. Readers should not equate a CHMP opinion with immediate hospital availability.
What remains uncertain?
European Commission timing could slip past the companies' end-September expectation. National HTA and pricing will determine real access. Prior CHMP refusals of earlier leriglitazone packages underscore residual evidence risk if post-marketing data disappoint. U.S. FDA filing status was described as still ahead by the sponsors.
Related NovaPharma coverage
- CHMP July 2026: 12 New Medicines Recommended
- Acadia Daybu CHMP OK for Rett syndrome
- EMA Review of Apitegromab in Spinal SMA Delayed
Frequently Asked Questions
What did CHMP recommend for Nezglyal?
On 23–24 July 2026, EMA said CHMP adopted a positive opinion recommending marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone) for cerebral adrenoleukodystrophy. Minoryx and Neuraxpharm said the intended population is males with ALD aged 2–12 years with non–gadolinium-enhancing brain MRI lesions and a Neurological Functional Score of 0 or 1.
What evidence supported the opinion?
The companies said the opinion rests on the Phase 2/3 NEXUS study plus real-world compassionate-use evidence. They described paediatric patients as clinically and radiologically stable after more than 96 weeks of treatment or before haematopoietic stem-cell transplantation. There are currently no approved pharmacological treatments for cALD in the EU, per the companies.
When could European Commission approval arrive?
Minoryx and Neuraxpharm said they expect European Commission approval by the end of September 2026. A positive CHMP opinion is not yet a marketing authorisation; pricing and access remain national decisions after EC authorisation.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Nezglyal.
Unlock full calendar →Minoryx Therapeutics pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…